PepGen Reports Data from Phase 1 Trial of PGN-EDO51
PepGen today shared data from its Phase I trial of PGN-EDO51 in healthy volunteers. PGN-EDO51 is an PMO-exon skipping therapy bound to a peptide which improves uptake into muscle cells, and targets those amenable to…Learn More
